Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (NOVAVAX)) | NOVAVAX | UNK | 6024MF020 | OT / LA |
Minimal side effects no nearly as intense as with mRNA; Very mild body aches; This non serious initial spontaneous report was reported by a Nurse via Contact Center (MI No. NOV25-00655) and concerns a 65-year-old Female who experienced "MINIMAL SIDE EFFECTS NO NEARLY AS INTENSE AS WITH MRNA" and "VERY MILD BODY ACHES" on unknown dates after receiving Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula) on 19-Nov-2024. At the time of the report, the outcome of the Adverse event and Pain was Unknown. A discrepancy was identified in the source document. The patient's age group was reported as adult, but was captured as elderly according to the age of 65-years.; Sender's Comments: This 65-year-old Female experienced Adverse event and Pain after vaccination with Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula). The events Adverse event and Pain were reported as non-serious. Based on the spontaneous nature of the report, the causal relationship between Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula) and Adverse event and Pain is considered Possible.
Bone marrow disorder
Medical History/Concurrent Conditions: COVID-19; Osteoporosis; SARS-CoV-2 rapid diagnostic test; Smoldering myeloma
ELETRIPTAN; AZELASTINE; CALCIUM CITRATE; VIT D3; MAGNESIUM GLYCINATE; VIT B 12 COMPLEX